Cord blood banking is still a rather young field. Many issues require further data and the hope is that this interactive web site can facilitate the identification of areas of uncertainty and to begin to develop a network to discuss some of the issues. For example, is the quality of a cord blood unit to be judged by TNC, viability using trypan blue or other methods, CD34+, CFUs, and/or other criteria? Which of the various methods of collection and processing, which vary significantly among cord blood banks, are optimal? Are cord blood banks economically viable, if so, will they be able to survive economic considerations surrounding rigid regulatory scrutiny?

You are invited to participate in the interactive forum.

The information in the following topics summarizes present information. Simply click on any of the topics listed below to see an annotated bibliography of recent data pertinent to that topic. You may also search for any topic and/or author by clicking on the SEARCH link in the navigation bar to access our comprehensive site search feature.

Please note that a link to an online abstract or full text version of each article is provided, if publicly available. Individuals with subscriptions to the journal may have online access to full text articles with a member sign-in on the journal's website. ASH members have online access to all full text articles published in Blood (initial sign-in required).

CordBloodForum.org welcomes questions and comments.

0.	THE TOP TEN
I.	RECENT REVIEWS
II.	TRANSPLANTATION OF ADULTS
III.	MULTI-CORD TRANSPLANTS
IV.	REDUCED INTENSITY AND NON-MYELOABLATIVE TRANSPLANTS
	i.	CORD BLOOD TRANSPLANTS
	ii.	MARROW AND PBSC TRANSPLANTS
V.	DONOR SELECTION FOR UNRELATED CORD BLOOD TRANSPLANTATION
VI.	AVAILABILITY AND TIME REQUIRED TO OBTAIN CORD BLOOD VERSUS BONE MARROW
VII.	CORD BLOOD TRANSPLANTATION IN CHILDREN
	i.	MALIGNANT DISORDERS
	ii.	CONGENITAL DISORDERS
	iii.	ACQUIRED NON-MALIGNANT DISORDERS
VIII.	GRAFT-VERSUS HOST DISEASE (GVHD)
	i.	GVHD IN BMT AND PBSC HEMATOPOIETIC CELL TRANSPLANTS
IX.	HLA MATCHING
X.	GRAFT-VERSUS-LEUKEMIA (GVL) ACTIVITY
XI.	RECENT CORD BLOOD TRANSPLANTATION CONFERENCES
XII.	SICKLE CELL DISEASE AND THALASSEMIA
	i.	SICKLE CELL DISEASE
		A. CLINICAL ASPECTS
		B. NEUROLOGIC COMPLICATIONS
		C. BONE MARROW AND PBSC TRANSPLANTATION
		D. UMBILICAL CORD BLOOD TRANSPLANTATION
	ii.	THALASSEMIA
		A. CLINICAL ASPECTS
		B. BONE MARROW AND PBSC TRANSPLANTATION
		C. UMBILICAL CORD BLOOD TRANSPLANTATION
		D. IRON OVERLOAD AND CHELATION
XIII.	IMMUNE RECONSTITUTION
XIV.	ADVERSE EVENTS IN CORD BLOOD TRANSPLANTATION
	i.	INFECTIONS (OTHER THAN EBV)
	ii.	EBV INFECTIONS / POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD)
	iii.	IMMUNE CYTOPENIA
	iv.	DONOR-DERIVED LEUKEMIA
	v.	MISCELLANEOUS
XV.	NEW CONCEPTS IN CORD BLOOD TRANSPLANTATION
	i.	ADOPTIVE IMMUNOTHERAPY AFTER CBT
	ii.	CO-TRANSPLANTATION OF CORD BLOOD UNITS AND MOBILIZED STEM CELLS FROM A THIRD PARTY DONOR
	iii.	PREIMPLANTATION GENETIC DIAGNOSIS
	iv.	IN-VIVO EXPANSION OF CORD BLOOD STEM CELLS
	v.	SERIAL TRANSPLANTATION RESULTING IN TOLERANCE
XVI.	STEM CELL PLASTICITY AND REGENERATIVE MEDICINE
XVII.	RELATED CORD BLOOD TRANSPLANTATION
XVIII.	EX-VIVO EXPANSION OF HEMATOPOIETIC PROGENITOR CELLS
XIX.	MISCELLANEOUS TOPICS
	i.	MESENCHYMAL STEM CELLS
	ii.	GRANULOCYTE TRANSFUSION
	iii.	REGULATORY ISSUES
	iv.	AUTOIMMUNE DISEASES
	v.	HIV POSITIVE PATIENTS
	vi.	ACUTE RADIATION INJURY
	vii.	OTHER ITEMS
XX.	ARTICLES REGARDING BMT AND/OR PBSC WITH RELEVANCE TO CORD BLOOD TRANSPLANTATION
XXI.	CORD BLOOD BANKING
	i.	OVERVIEW
	ii.	INFORMED CONSENT
	iii.	STRATEGIES FOR CORD BLOOD COLLECTION
	iv.	PROCESSING, CYROPRESERVATION AND INFUSION
	v.	QUALITY ISSUES
XXII.	BOOKS
XXIII.	AMERICAN SOCIETY OF HEMATOLOGY (ASH) ABSTRACTS 2007

Back to Top